{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:03Z","timestamp":1786119603723,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/wnf.0b013e3181f8d513","type":"journal-article","created":{"date-parts":[[2010,11,13]],"date-time":"2010-11-13T04:19:38Z","timestamp":1289621978000},"page":"312-316","source":"Crossref","is-referenced-by-count":88,"title":["Severe Depression, Suicide Attempts, and Ideation During the Use of Interferon Beta by Patients With Multiple Sclerosis"],"prefix":"10.1097","volume":"33","author":[{"given":"Yara Dadalti","family":"Fragoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Regina Comini","family":"Frota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juarez Silva","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaina Silveira","family":"Noal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Vinicius Magno","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Diniz","family":"da Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Finkelsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/14712598.7.4.535","article-title":"Interferon beta 1a for the treatment of multiple sclerosis.","volume":"7","author":"Clerico","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"R2-9-20210203","first-page":"CD002002","article-title":"Interferon in relapsing-remitting multiple sclerosis.","volume":"4","author":"Rice","year":"2001","journal-title":"Cochrane Database Syst"},{"key":"R3-9-20210203","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/1352458506070748","article-title":"Long-term emotional state of multiple sclerosis patients treated with interferon beta.","volume":"12","author":"Porcel","year":"2006","journal-title":"Mult Scler"},{"issue":"suppl 4","key":"R4-9-20210203","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/S0035-3787(09)72128-9","article-title":"Depression in multiple sclerosis.","volume":"165","author":"Lebrun","year":"2009","journal-title":"Rev Neurol Paris"},{"key":"R5-9-20210203","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00002826-200301000-00002","article-title":"Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report.","volume":"26","author":"Goeb","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"R6-9-20210203","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1590\/S0004-282X2002000500007","article-title":"Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.","volume":"60","author":"Lana-Peixoto","year":"2002","journal-title":"Arq Neuropsiquiatr"},{"key":"R7-9-20210203","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/archneur.56.10.1263","article-title":"Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.","volume":"56","author":"Mohr","year":"1999","journal-title":"Arch Neurol"},{"issue":"suppl 1","key":"R8-9-20210203","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0022-510X(09)70011-5","article-title":"Multiple sclerosis beyond EDSS: depression and fatigue.","volume":"277","author":"Ziemssen","year":"2009","journal-title":"J Neurol Sci"},{"key":"R10-9-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11011-008-9114-5","article-title":"Neuropsychiatric disorders related to interferon and interleukins treatment.","volume":"24","author":"Myint","year":"2009","journal-title":"Metab Brain Dis"},{"key":"R11-9-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon alpha: recognition and management.","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"R12-9-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/mp.2009.116","article-title":"CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.","volume":"15","author":"Raison","year":"2010","journal-title":"Mol Psychiatry"},{"key":"R13-9-20210203","first-page":"267","article-title":"Empirical delineation of the probability spectrum of adverse drug reactions.","volume":"29","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R14-9-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A reliable method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"R15-9-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"R16-9-20210203","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/1352458510365157","article-title":"Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study.","volume":"16","author":"LoFermo","year":"2010","journal-title":"Mult Scler"},{"key":"R17-9-20210203","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1590\/S0004-282X2009000400017","article-title":"Psychiatric disorders in multiple sclerosis patients.","volume":"67","author":"Fazzito","year":"2009","journal-title":"Arq Neuropsiquiatr"},{"key":"R18-9-20210203","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1352458509105426","article-title":"Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.","volume":"15","author":"Carroll","year":"2009","journal-title":"Mult Scler"},{"key":"R19-9-20210203","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14712591003702361","article-title":"Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.","volume":"10","author":"Boyko","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"R20-9-20210203","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/14656560802677882","article-title":"High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.","volume":"10","author":"Hartung","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R21-9-20210203","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00415-002-0725-0","article-title":"Multiple sclerosis, interferon beta-1b and depression A prospective investigation.","volume":"249","author":"Feinstein","year":"2002","journal-title":"J Neurol"},{"key":"R22-9-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.31887\/DCNS.2009.11.4\/felotrich","article-title":"Major depression during interferon alpha treatment: vulnerability and prevention.","volume":"11","author":"Lotrich","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"R23-9-20210203","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/070674370905400906","article-title":"Managing depression during hepatitis C treatment.","volume":"54","author":"Sockalingam","year":"2009","journal-title":"Can J Psychiatry"},{"key":"R24-9-20210203","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijnurstu.2009.08.002","article-title":"Depression and protective factors of mental health in people with hepatitis C: a questionnaire survey.","volume":"47","author":"Erim","year":"2010","journal-title":"Int J Nurs Stud"},{"key":"R25-9-20210203","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00023210-200721060-00003","article-title":"Assessing the role of drugs in suicidal ideation and suicidality.","volume":"21","author":"Reith","year":"2007","journal-title":"CNS Drugs"},{"key":"R26-9-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eurpsy.2005.09.013","article-title":"Psychiatric side effects of interferon-beta in multiple sclerosis.","volume":"21","author":"Goeb","year":"2006","journal-title":"Eur Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201011000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:42:34Z","timestamp":1786041754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201011000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181f8d513","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}